Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 15;6(3):ofz080.
doi: 10.1093/ofid/ofz080. eCollection 2019 Mar.

In-depth Sampling of High-risk Populations to Characterize HIV Transmission Epidemics Among Young MSM Using PrEP in France and Quebec

Antoine Chaillon  1 , Constance Delaugerre  2   3 , Bluma Brenner  4 , Alix Armero  2 , Catherine Capitant  5 , Marie Laure Nere  2 , Nicolas Leturque  5 , Gilles Pialoux  6 , Eric Cua  7 , Cecile Tremblay  8 , Davey M Smith  1 , Cecile Goujard  9   10 , Laurence Meyer  5   9   10 , Jean Michel Molina  3   11 , Marie Laure Chaix  2   3
Affiliations

In-depth Sampling of High-risk Populations to Characterize HIV Transmission Epidemics Among Young MSM Using PrEP in France and Quebec

Antoine Chaillon et al. Open Forum Infect Dis. .

Abstract

Background: A better understanding of HIV transmission dynamics among populations at high risk is important for development of prevention strategies. We determined HIV transmission networks from infected individuals enrolled in the pre-exposure prophylaxis (PrEP) IPERGAY trial in combination with the ANRS PRIMO and Montreal PHI cohorts to identify and characterize active clusters of transmission in this high-risk population.

Methods: Genotypic resistance tests were performed on plasma samples from 31 IPERGAY participants. Reverse transcriptase sequences were analyzed in combination with unique HIV pol sequences from 1351 individuals enrolled in the PRIMO ANRS cohort (1999-2014) and 511 individuals enrolled in the Montreal PHI cohort (1996-2016). Network analyses were performed to infer putative relationships between all participants.

Results: Overall, 1893 participants were included. Transmission network analyses revealed that 14 individuals (45.2%) from the IPERGAY trial were involved in 13 clusters sampled over a median period (interquartile range) of 2 (0.3-7.8) years, including 7 dyads and 6 larger clusters ranging from 4 to 28 individuals. When comparing characteristics between clustering individuals enrolled in the PRIMO cohort (n = 377) and in IPERGAY (n = 14), we found that IPERGAY participants had a higher viral load (5.93 vs 5.20 log10 copies/mL, P = .032) and reported a higher number of partners in the last 2 months (P < .01).

Conclusions: These results demonstrate high rates of HIV transmission clustering among young high-risk MSM enrolled in the IPERGAY trial. In-depth sampling of high-risk populations may help to uncover unobserved transmission intermediaries and improve prevention efforts that could be targeted to the most active clusters.

Keywords: HIV; MSM; PrEP; clustering; network.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
HIV transmission network for IPERGAY participants and the ANRS PRIMO ANRS and Montreal PHI cohorts. Genetic data mapped onto participant cohort. Edges indicate genetic linkage (<0.015 substitutions/site for B and <0.01 substitutions/site for non-B). Red dot circled cluster indicates cluster with 1 IPERGAY and 5 French ANRS PRIMO sequences harboring the same K103N mutation. Blue dot circled cluster indicates partial sampling of a larger previously reported cluster (>40 sequences) including sequences from other cities in Quebec (Sherbrooke, Quebec, and Montreal).
Figure 2.
Figure 2.
HIV transmission network for IPERGAY participants and the ANRS PRIMO ANRS and Montreal PHI cohorts. Only clusters including participants from the ANRS IPERGAY trial are shown. Genetic data mapped onto participants’ reported main transmission risk. Red dot circled cluster indicates cluster with 1 IPERGAY and 5 French ANRS PRIMO sequences harboring the same K103N mutation. Blue dot circled cluster indicates partial sampling of a larger previously reported cluster (>40 sequences) including sequences from other cities in Quebec (Sherbrooke, Quebec, and Montreal).
See this image and copyright information in PMC

References

    1. Grant RM, Lama JR, Anderson PL, et al. iPrEx Study Team Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587–99. - PMC - PubMed
    1. Baeten JM, Donnell D, Ndase P, et al. Partners PrEP Study Team Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399–410. - PMC - PubMed
    1. Choopanya K, Martin M, Suntharasamai P, et al. Bangkok Tenofovir Study Group Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083–90. - PubMed
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. TDF2 Study Group Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423–34. - PubMed
    1. Molina JM, Capitant C, Spire B, et al. ANRS IPERGAY Study Group On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373:2237–46. - PubMed